Figure 6. Combined treatment with ABT263 and TIC10/ONC201 results in an enhanced inhibition of tumor growth in vivo.
5 × 105 MGPP-3 glioblastoma cells were implanted subcutaneously. After tumor formation animals were treated intraperitoneally with vehicle (n = 5 tumors), ABT263 (25 mg/kg; n = 6 tumors), TIC10/ONC201 (25 mg/kg; n = 6 tumors) or both agents (n = 6 tumors) 3 times a week for 2 weeks. A. tumor growth curves showing the increase in tumor size for each treatment group. Data are presented as mean and SEM. B. representative photographs of the tumors; A = ABT263, T = TIC10/ONC201. C. quantification and statistical analysis (Student's t-test) of the tumors of the different treatment groups 22 days after tumor implantation. D. graphical representation of the bodyweight of the animals on day 22. Data are presented as mean and SEM. E. representative microphotographs showing the histological morphology (H & E staining) of the indicated organs among representative animals receiving treatment either with vehicle or the combination of ABT263 and TIC10/ONC201. Magnification, x40; scale bar, 100 μm.